(Beta-blockers in cardiovascular diseases 2025 - editorial)

Jiří Vítovec

Cor Vasa 2025, 67(Suppl.2):5-6 | DOI: 10.33678/cor.2025.060  

(Current view on beta-blockers in the therapy of heart failure)

Filip Málek

Cor Vasa 2025, 67(Suppl.2):7-13 | DOI: 10.33678/cor.2024.106  

Beta-blockers are drugs demonstrably modifying course of heart failure with reduced ejection fraction. Beta-blockers reduce all cause mortality, risk of sudden death and risk of death due to worsening of heart failure. They reduce cardiovascular mortality and risk of hospitalizations; they influence morbidity of the patients positively. The treatment is usually well tolerated. It is necessary to reach maximal tolerated drug dose, the effect is dose-dependent. Beta-blockers rightfully belong to the group of fundamental drugs for the treatment of heart failure.

(Beta-blockers in the secondary prevention of myocardial infarction with respect to recent results of ABYSS and REDUCE-AMI trials)

Petr Janský

Cor Vasa 2025, 67(Suppl.2):14-17 | DOI: 10.33678/cor.2025.049  

Beta-blockers the prognosis patients myocardial Their is in who signs cardiac or ventricular However, to European the positive also in patients. of that shown a in and have conducted patients major attacks at time diagnosis modern and acute long were available. new trials needed investigate the benefits in with left systolic who being with pharmacotherapy. The contradictory results of the recently published REDUCE-AMI and ABYSS studies do not cur- rently warrant a change in the recommendations for secondary prevention of myocardial infarction.

(Beta-blockers in the treatment of hypertension)

Renata Cífková

Cor Vasa 2025, 67(Suppl.2):18-25 | DOI: 10.33678/cor.2025.047  

Beta-blockers are currently among the five major classes of antihypertensive drugs with a proven reduction in cardiovascular (CV) morbidity and mortality. The latest recommendations of the European Society of Hypertension (ESH) have reassessed their position in the treatment of hypertension and have included them among the drugs of the first choice in the treatment of hypertension. Prevention of cardiovascular (CV) complications in hypertension has been documented by large clinical trials for atenolol, metoprolol, oxprenolol, and propranolol. Beta-blockers are widely used in the management of hypertension accompanied by comorbidities such as chronic...

(Beta-blockers in cardiac arrythmias)

Miloš Táborský, Milena Kubíčková

Cor Vasa 2025, 67(Suppl.2):26-31 | DOI: 10.33678/cor.2025.048  

Beta-blockers have long been among the basic antiarrhythmic drugs. They are indicated for practically all types of arrhythmias except bradycardias. It is a large group of antiarrhythmic drugs that differ in their pharmacokinetic and chemical properties. Some of them block beta-adrenergic receptors selectively, while others act non-selectively. As a result, they reduce the influence of the sympathetic nervous system on the heart, have negative inotropic, chronotropic, bathmotropic and dromotropic effects. Although they have been present in medicine since the early 1960s, they still play a crucial role in the treatment of cardiac arrhyth- mias. They...

(Current position of beta-blockers in acute cardiac care)

Tomáš Hnát^*, Petr Kala^*, Dagmar Vondráková, Petr Ošťádal

Cor Vasa 2025, 67(Suppl.2):33-39 | DOI: 10.33678/cor.2025.058  

Beta-adrenergic blocking agents represent one of the cornerstones of pharmacotherapy in cardiology. This review article describes the effect of beta-blockers on the cardiovascular system, compares different types of currently available medications and discusses the use of beta-blockers in the most common acute situations encountered in cardiac intensive care units.